Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK961081 bronchodilation with add-on salbutamol and ipratropium in COPD
2008-000725-18Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of batefenterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoints: Maximal increase from pre-dose short-acting bronchodilator in FEV1 at 1 hour, Maximal increase from pre-dose short-acting bronchodilator in FEV1 at 12 hours and 1 more. Started Feb 2008; status: completed.
02
Drugs
batefenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-000725-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000725-18.